Brief: Bio-Path Holdings Announces Successful Completion Of First Dose Cohort In Phase 1/1B Clinical Trial Of Bp1001-A In Solid Tumors
17/07/2023 12:02
July 17 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF FIRST
DOSE
COHORT IN PHASE 1/1B CLINICAL TRIAL OF BP1001-A IN SOLID TUMORS
* BIO PATH HOLDINGS INC - NO PATIENT EXPERIENCED ANY
TREATMENT
RELATED ADVERSE EVENTS OR ANY ADVERSE EVENTS DEEMED RELATED TO
STUDY DRUG
Source text for Eikon: ID:nGNX9tjCk0
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia